Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE Our preclinical work indicates that anlotinib acts as a novel inhibitor of VEGFR2 and MET that blocks tumorigenesis in osteosarcoma, which could be translated into future clinical trials. 30719715 2019
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 AlteredExpression disease BEFREE Expression levels of miR-206, PAX3, and MET mRNA were explored in paired OS and adjacent tissue specimens. 30666838 2019
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE In rare tumour types we observed, amongst others, a predicted overexpression rate of 55% of samples for CD22 and 55% for ENPP3 in adrenocortical carcinomas, 81% for CD74 and 81% for FGFR3 in osteosarcomas, and 95% for c-MET in uveal melanomas. 29045509 2017
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 AlteredExpression disease BEFREE Our data assessed specific miRNA profiling deregulation in OS clinical samples and suggest that the expression of miR-1 and miR-133b may control cell proliferation and cell cycle through MET protein expression modulation. 23229283 2013
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease CTD_human Met interacts with EGFR and Ron in canine osteosarcoma. 22235915 2013
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE The MET oncogene transforms human primary bone-derived cells into osteosarcomas by targeting committed osteo-progenitors. 22367914 2012
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 AlteredExpression disease BEFREE The Met receptor tyrosine kinase (RTK) is aberrantly expressed in human osteosarcoma and is an attractive molecular target for cancer therapy. 19402129 2009
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 AlteredExpression disease BEFREE Overexpression of MET, obtained by lentiviral vector-mediated gene transfer, resulted in the conversion of primary human osteoblasts into osteosarcoma cells, displaying the transformed phenotype in vitro and the distinguishing features of human osteosarcomas in vivo. 16651428 2006
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease LHGDN c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells. 14524531 2003
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease LHGDN We analyzed the effect of the MET receptor activation in five human osteosarcoma cell lines evaluating the levels of HGF-dependent activation of MAPK and PKB/AKT as biochemical readouts of mitogenic and invasive responses, respectively. 12709413 2003
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 AlteredExpression disease BEFREE We previously demonstrated that the MET oncogene was aberrantly expressed in a high percentage of human osteosarcomas. 10815826 2000
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 AlteredExpression disease BEFREE We have previously found that bone sarcomas express high levels of Met/HGF receptor while in some cases the ligand HGF is co-expressed with the receptor, activating an autocrine loop. 10867643 2000
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 AlteredExpression disease BEFREE The finding of Met/HGF receptor overexpression in all of the osteosarcomas suggests a role for the met proto-oncogene in the pathogenesis of this tumor. 8863670 1996
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 AlteredExpression disease BEFREE These data suggest that activation of the Met/HGF receptor by a paracrine or an autocrine mechanism might play a role in the particularly aggressive behaviour of osteosarcomas. 7862451 1995
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE The TPR-MET oncogenic rearrangement was originally observed in an in vitro transformed human osteosarcoma cell line. 2052572 1991